Chlorpropamide
- Atc Codes:A10BB02
- CAS Codes:94-20-2
- PHARMGKB ID:94-20-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Cyprus: Chlorpropamide; Italy: Clorprop, Diabemide; Luxembourg: Diabinese; Poland: Chlorpropamid, Diabinese; Spain: Diabinese.
North America
Canada: Chlorpropamide, Novo-Propamide; USA: Chlorpropamide, Diabinese.
Latin America
Argentina: Diabenese, Idle, Trane; Brazil: Diabecontrol-Clorpropamida, Diabenese, Glicorp, Pramidalin; Mexico: Apoprob, Bioness, Diabenese.
Asia
Japan: Abemide.
Drug combinations
Chlorpropamide and Metformin
Chemistry
Chlorpropamide: C~10~H~13~ClN~2~O~3~S. Mw: 276.74. (1) Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]-; (2) 1-[(p-Chlorophenyl)sulfonyl]-3-propylurea. CAS-94-20-2.
Pharmacologic Category
Antidiabetic Agents; Sulfonylureas. (ATC-Code: A10BB02).
Mechanism of action
Stimulates insulin release from the pancreatic β-cells. Reduces glucose output from the liver.
Therapeutic use
Type 2 diabetes mellitus.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. Crosses the placenta. Teratogenic effects reported (unknown if related to medication or to uncontrolled diabetes). Nonteratogenic adverse effects (e.g. severe neonatal hypoglycemia, increased perianatal mortality) also associated with maternal use (oral agents generally not recommended as routine management of type 2 diabetes mellitus during pregnancy; insulin is drug of choice). Use not recommended during lactation (potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk).
Unlabeled use
Neurogenic diabetes insipidus.
Contraindications
Hypersensitivity to chlorpropamide, sulfonylureas, sulfonamides, or any component of the formulation. Type 1 diabetes mellitus (insulin-dependent). Diabetic ketoacidosis.
Warnings and precautions
All sulfonylurea drugs are capable of producing severe hypoglycemia. Use in sulfonylurea or sulfonamide allergy is specifically contraindicated.